Association Between e-Cigarette Use and Depression in the Behavioral Risk Factor Surveillance System, 2016-2017.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 12 2019
Historique:
entrez: 5 12 2019
pubmed: 5 12 2019
medline: 24 6 2020
Statut: epublish

Résumé

The prevalence of the use of electronic cigarettes (e-cigarettes) in the United States has grown rapidly since their introduction to the market more than a decade ago. While several studies have demonstrated an association between combustible cigarette smoking and depression, the association between e-cigarette use and depression has not been thoroughly studied. To examine the association between e-cigarette use and depression in a nationally representative sample of the adult population in the United States. Cross-sectional study of the Behavioral Risk Factor Surveillance System database, 2016 to 2017. The Behavioral Risk Factor Surveillance System is the largest national telephone-based survey of randomly sampled adults in the United States. A total of 892 394 participants with information on e-cigarette use and depression were included. Data analysis was conducted in May 2019. Electronic cigarette use status defined by self-report as never, former, or current use. Self-reported history of a clinical diagnosis of depression. Of the 892 394 participants (414 326 [29.0%] aged ≥60 years; 502 448 [51.3%] women), there were 28 736 (4.4%) current e-cigarette users, of whom 13 071 (62.1%) were aged between 18 and 39 years. Compared with never e-cigarette users, current e-cigarette users were more likely to be single, male, younger than 40 years, and current combustible cigarette smokers (single, 120 797 [24.3%] vs 10 517 [48.4%]; men, 318 970 [46.6%] vs 14 962 [60.1%]; aged 18-39 years, 129 085 [32.2%] vs 13 071 [62.1%]; current combustible cigarette use, 217 895 [7.9%] vs 8823 [51.8%]). In multivariable adjusted models, former e-cigarette users had 1.60-fold (95% CI, 1.54-1.67) higher odds of reporting a history of clinical diagnosis of depression than never users, whereas current e-cigarette users had 2.10 (95% CI, 1.98-2.23) times higher odds. Additionally, higher odds of reporting depression were observed with increased frequency of use among current e-cigarette users compared with never users (daily use: odds ratio, 2.39; 95% CI, 2.19-2.61; occasional use: odds ratio, 1.96; 95% CI, 1.82-2.10). Similar results were seen in subgroup analyses by sex, race/ethnicity, smoking status, and student status. This study found a significant cross-sectional association between e-cigarette use and depression, which highlights the need for prospective studies analyzing the longitudinal risk of depression with e-cigarette use. If confirmed by other study designs, the potential mental health consequences may have regulatory implications for novel tobacco products.

Identifiants

pubmed: 31800073
pii: 2756260
doi: 10.1001/jamanetworkopen.2019.16800
pmc: PMC6902792
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1916800

Subventions

Organisme : NHLBI NIH HHS
ID : P50 HL120163
Pays : United States
Organisme : NHLBI NIH HHS
ID : U54 HL120163
Pays : United States

Références

Prev Med. 2016 Dec;93:14-20
pubmed: 27612572
JAMA Pediatr. 2017 Aug 1;171(8):788-797
pubmed: 28654986
Clin Pharmacokinet. 1999 Jun;36(6):425-38
pubmed: 10427467
J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1602-10
pubmed: 8973066
Subst Abus. 2019;40(1):7-10
pubmed: 30883295
PLoS One. 2019 Aug 8;14(8):e0220763
pubmed: 31393922
Ann Intern Med. 2018 Oct 2;169(7):429-438
pubmed: 30167658
JAMA Pediatr. 2017 Mar 1;171(3):209-210
pubmed: 27928577
Tob Control. 2014 Mar;23(2):133-9
pubmed: 23467656
N Engl J Med. 2011 Jul 21;365(3):196-8
pubmed: 21774707
Environ Res. 2018 Oct;166:269-275
pubmed: 29908458
JAMA. 2000 Aug 9;284(6):699-705
pubmed: 10927777
Psychiatr Serv. 2008 Dec;59(12):1383-90
pubmed: 19033164
BMJ Case Rep. 2018 Oct 2;2018:null
pubmed: 30279252
Environ Health Perspect. 2018 Feb 21;126(2):027010
pubmed: 29467105
Annu Rev Clin Psychol. 2009;5:409-31
pubmed: 19327035
Drug Alcohol Depend. 2013 Aug 1;131(3):214-21
pubmed: 23746429
Addict Behav. 2019 Mar;90:85-91
pubmed: 30368023
Ann N Y Acad Sci. 2015 Mar;1340:65-74
pubmed: 25557889
Addict Behav. 2009 Jun-Jul;34(6-7):491-7
pubmed: 19217720
J Am Heart Assoc. 2018 Jul 14;7(14):
pubmed: 30007934
Tob Control. 2014 May;23 Suppl 2:ii30-5
pubmed: 24732160
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
Ann Intern Med. 2019 Jan 1;170(1):70-71
pubmed: 30304343
Lancet Psychiatry. 2018 Sep;5(9):739-746
pubmed: 30099000
Tob Control. 2019 Nov;28(6):623-628
pubmed: 30733312
Biol Trace Elem Res. 2019 Apr;188(2):295-315
pubmed: 29974385
J Addict Dis. 1998;17(1):35-46
pubmed: 9549601
J Gen Physiol. 2019 Jun 3;151(6):714-717
pubmed: 30902836
Inhal Toxicol. 2018 Feb;30(2):78-88
pubmed: 29564955
Tob Control. 2014 Jul;23 Suppl 3:iii48-53
pubmed: 24824516
JAMA Pediatr. 2018 Feb 1;172(2):181-187
pubmed: 29297010
Int J Environ Res Public Health. 2016 Dec 23;14(1):
pubmed: 28025560
Prev Med. 2017 Mar;96:73-78
pubmed: 28024859
JAMA. 1990 Sep 26;264(12):1546-9
pubmed: 2395194
BMJ. 2015 Sep 21;351:h4065
pubmed: 26391240

Auteurs

Olufunmilayo H Obisesan (OH)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas.
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland.

Mohammadhassan Mirbolouk (M)

Department of Medicine, Yale New Haven Hospital, New Haven, Connecticut.

Albert D Osei (AD)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas.
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland.

Olusola A Orimoloye (OA)

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

S M Iftekhar Uddin (SMI)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas.
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland.

Omar Dzaye (O)

Johns Hopkins University, Baltimore, Maryland.
Department of Radiology and Neuroradiology, Charité, Berlin, Germany.

Omar El Shahawy (O)

Section on Tobacco, Alcohol, and Drug Use, Department of Population Health, School of Medicine, New York University, New York.
Public Health Research Center, New York University, Abu Dhabi, United Arab Emirates.

Mahmoud Al Rifai (M)

Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.

Aruni Bhatnagar (A)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas.
University of Louisville, Louisville, Kentucky.

Andrew Stokes (A)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas.
Boston University, Boston, Massachusetts.

Emelia J Benjamin (EJ)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas.
Boston University, Boston, Massachusetts.

Andrew P DeFilippis (AP)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas.
University of Louisville, Louisville, Kentucky.

Michael J Blaha (MJ)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas.
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH